EP1198462B1 - Procede de preparation d'un derive de 10,11-methanodibenzosuberane - Google Patents

Procede de preparation d'un derive de 10,11-methanodibenzosuberane Download PDF

Info

Publication number
EP1198462B1
EP1198462B1 EP00935852A EP00935852A EP1198462B1 EP 1198462 B1 EP1198462 B1 EP 1198462B1 EP 00935852 A EP00935852 A EP 00935852A EP 00935852 A EP00935852 A EP 00935852A EP 1198462 B1 EP1198462 B1 EP 1198462B1
Authority
EP
European Patent Office
Prior art keywords
compound
formula
acid
preparing
iii
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
EP00935852A
Other languages
German (de)
English (en)
Other versions
EP1198462A1 (fr
Inventor
Bret Anthony Astleford
Charles Jackson Barnett
Michael Edward Kobierski
Thomas Michael Wilson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eli Lilly and Co
Original Assignee
Eli Lilly and Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly and Co filed Critical Eli Lilly and Co
Publication of EP1198462A1 publication Critical patent/EP1198462A1/fr
Application granted granted Critical
Publication of EP1198462B1 publication Critical patent/EP1198462B1/fr
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/06—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by halogen atoms or nitro radicals
    • C07D295/073—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by halogen atoms or nitro radicals with the ring nitrogen atoms and the substituents separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms

Definitions

  • This invention relates to the art of synthetic organic chemistry. Specifically, the invention is a process to prepare (2R)- anti -5- ⁇ 3-[4-(10,11-difluoromethanodibenzosuber-5-yl)piperazin-1-yl]-2-hydroxypropoxy ⁇ quinoline trihydrochloride salt of formula I:
  • U.S. patents 5,643,909 and 5,654,304 disclose a series of 10,11-methanobenzosuberane derivatives useful in enhancing the efficacy of existing cancer chemotherapeutics and for treating multidrug resistance.
  • (2R)-anti-5- ⁇ 3-[4-(10,11-difluoromethanodibenzosuber-5-yl)piperazin-1-yl]-2-hydroxypropoxy ⁇ quinoline trihydrochloride disclosed therein, is currently under development as a pharmaceutical agent.
  • the present invention involves an improved process to prepare (2R) - anti -5- ⁇ 3-[4-(10,11-difluoromethanodibenzosuber-5-yl)piperazin-1-yl]-2-hydroxypropoxy ⁇ quinoline trihydrochloride (compound of formula I), wherein the chemistry is more efficient and adaptable to large scale processing in anticipation of development needs.
  • the process of the present invention uses piperazine to react with the (1a ⁇ ,6 ⁇ ,10b ⁇ )-6-halo-1,1-difluoro-1,1a,6,10b-tetrahydrodibenzo[ a , e ]cyclopropa[ c ]cycloheptene compound or derivative, instead of formylpiperazine.
  • the process of the present invention is advantageous because piperazine is readily available in commercial quantities whereas 1-formylpiperazine, which was utilized in the process disclosed in U.S. Patent 5,643,909 is often not readily available in commercial quantities. Additionally piperazine enjoys a significant cost advantage over 1-formylpiperazine.
  • the present invention provides a process for preparing a compound of the formula (IVa) : wherein HX is an acid, comprising the steps of:
  • the present invention also provides a process for preparing a compound of formula (IVa), comprising the steps of:
  • the present invention also provides a process for preparing a compound of formula (I) from the anti stereoisomer IVa, according to the invention, comprising the steps of:
  • the present invention further provides a process for preparing the syn isomer compound (III) and pharmaceutically acceptable salts thereof, by the method of the invention.
  • halogenating agent refers to halogenic acids or other acidic groups capable of converting alcohols to halides.
  • Illustrative halogenating agents include hydrogen bromide, hydrogen chloride, hydrogen iodide, thionyl chloride, oxalyl chloride, phosphorus trichloride or pentachloride, and the like.
  • the term "pharmaceutically acceptable salt” refers to all non-toxic organic or inorganic acid addition salts.
  • Inorganic acids or “acidic groups” which form salts include those selected from the group comprising of hydrobromic acid, hydrochloric acid and camphorsulfonic acid.
  • a particularly preferred acidic group is hydrochloric acid.
  • Acid addition salts formed from these acids can exist in either hydrated or substantially anhydrous form, all of which are within the scope of this invention.
  • the compounds of formula II may be prepared according to the following steps illustrated in Scheme B, starting from 5H-dibenzo[a,d]cyclohepten-5-one (dibenzosuberenone), which is commercially available, e.g., from Aldrich Chemical Company, Milwaukee, Wis. Other reactants are likewise commercially available or may be readily prepared by those skilled in the art.
  • a particularly preferred embodiment of this invention provides a procedure that combines steps 1 and 2 (see Scheme B below) in one operational step.
  • Step 1 A solution of an alkali halodifluoro-acetate such as sodium chlorodifluoroacetate in a solvent (for example, glyme, diglyme) is added over a period of 4 to 8 hours (preferably 6 hours) to a solution of dibenzosuberenone (for example in diglyme) with stirring and under nitrogen, maintaining the reaction temperature at 160°-165° C.
  • a solvent for example, glyme, diglyme
  • dibenzosuberenone for example in diglyme
  • Other reaction temperatures may be employed depending upon the reactants used, as described in Ciganek et al., "Imine Analogues of Tricyclic Antidepressants," J . Med.
  • the 1,1-difluoro-1a,10b-dihydrodibenzo[a,e]cyclopropa[ c ]cyclohepten-6(1 H )-one is isolated and purified by conventional means, for example, the organic phase is washed with water, dried (e.g., over Na 2 SO 4 ), evaporated, and the residue is recrystallized (e.g., from ethanol, and optionally recrystallized again, e.g., from acetone/hexane).
  • Step 2 A solution of the 1,1-difluoro-1 a ,10 b -dihydrodibenzo[a,e]cyclopropa[ c ]cyclohepten-6(1 H )-one in a solvent (e.g., THF/methanol) is cooled typically to between 0° C and 25° C, and a reducing agent (e.g., lithium borohydride or sodium borohydride) is added in portions. The reaction mixture is allowed to come to room temperature and stirred for 1 to 5 hours preferably 2 hours, then poured into water. The product is isolated (e.g., by filtration) and purified by conventional means (e.g., washed with water and dried).
  • a solvent e.g., THF/methanol
  • steps 1 and 2 may be accomplished in one processing step by heating a solution of dibenzosuberenone in triethylene glycol dimethyl ether to between 180 °C and 210 °C, followed by slow addition of a solution of chlorodifluoroacetic acid, lithium salt in ethylene glycol dimethyl ether.
  • the ethylene glycol dimethyl ether is distilled from the reaction as the salt addition proceeded. Gas chromatographic analysis of an aliquot is utilized to indicate complete or near complete consumption of the 5 H -dibenzo[ a,d ]cyclohepten-5-one.
  • the reaction is cooled to ambient temperature and then combined with a mixture of ethyl acetate and diatomaceous earth.
  • the solids are removed by filtration and washed with ethyl acetate.
  • the washes and filtrate are combined and the ethyl acetate is removed by concentration under vacuum.
  • the concentrate is cooled, followed by addition of sodium borohydride solution sufficient to effect complete or near complete reduction.
  • the reaction is quenched by careful addition of a methanolic HCl solution.
  • the suspension is stirred for 30 minutes and the crude product is collected by filtration, washed with 1:1 methanol-water and dried to a dark brown solid.
  • Step 3 A solution of the (1a ⁇ ,6 ⁇ ,10b ⁇ )-1,1-difluoro-1,1a,6,10b-tetrahydrodibenzo[ a , e ]cyclopropa[ c ]cyclohepten-6-ol in a suitable solvent (e.g., dichloromethane) is cooled (e.g., in an ice bath) followed by addition of a halogenating agent.
  • Preferred halogenating agents are hydrogen bromide, hydrogen chloride, hydrogen iodide, thionyl chloride, oxalyl chloride, phosphorus trichloride or pentachloride, and the like. Most preferred are hydrogen chloride and hydrogen bromide.
  • the reaction is maintained at a temperature of between 40° to 70° C, preferably 50° C, for 2 to 5 hours (preferably 4 hours).
  • the reaction mixture is evaporated to dryness, affording a mixture of (1a ⁇ ,6 ⁇ ,10b ⁇ )-6-halo-1,1-difluoro-1,1,a,6,10b-tetrahydrodibenzo[ a , e ]cyclopropa[ c ]cycloheptene and the corresponding syn isomer (1a ⁇ ,6 ⁇ ,10b ⁇ )-6-halo-1,1-difluoro-1,1,a,6,10b-tetrahydrodibenzo[ a , e ]cyclopropa[ c ]cycloheptene.
  • the bromination reaction provides the anti-stereoisomer ((1a ⁇ ,6 ⁇ ,b ⁇ )-6-bromo-1,1-difluoro-1,1,a,6,10b-tetrahydrodibenzo[ a , e ]cyclopropa[ c ]-cycloheptene) (iii) exclusively.
  • Preparation of the (1a ⁇ ,6 ⁇ ,10b ⁇ )-6-bromo-1,1-difluoro-1,1,a,6,10b-tetrahydrodibenzo[ a , e ]cyclopropa[ c ]cycloheptene derivative (iii) is preferably accomplished by reacting the (1a ⁇ ,6 ⁇ ,10b ⁇ )-1,1-difluoro-1,1a,6,10b-tetrahydrodibenzo[ a , e ]cyclopropa[ c ]cyclohepten-6-ol (ii) with hydrogen bromide.
  • the mixture of syn and anti-stereoisomers (II) is preferably separated by crystallization of the syn stereoisomer from the acetonitrile reaction mixture. This is followed by removal of the remaining acetonitrile and replacement with hydrogen bromide, hydrogen chloride or camphorsulfonic acid and a solvent selected from methylene chloride, ethanol and ethyl acetate.
  • the purified (1a ⁇ ,6 ⁇ ,10b ⁇ )-1-(1,1-difluoro-1,1a,6,10b-tetrahydrodibenzo[ a , e ]cyclopropa[ c ]cyclohepten-6-yl)-piperazine, acid salt compound (IVa) is afforded after crystallization.
  • the isolated syn isomer product III from above may be dried, used directly or optionally further purified by methods known in the arts, e.g., crystallization, chromatography.
  • the syn isomer compound of formula (III) may optionally be acidified to form a pharmaceutically acceptable acid salt.
  • the acid salt compound (IVa) may be converted to the compounds of formula I as illustrated in scheme C below:
  • Acid salts of (V) may be prepared by methods known to those skilled in the art.
  • the preferred trihydrochloride salt, anti -5- ⁇ 3-[4-(10,11-difluoromethano-dibenzosuber-5-yl)piperazin-1-yl]-2-hydroxypropoxy ⁇ quinoline trihydrochloride (I) may be prepared by addition of hydrogen chloride in diethyl ether (e.g., 3 molar equivalents to form the trihydrochloride (salt) at 0-15 °C followed by, for example, recrystallization from ethanol.
  • syn isomer compound of formula (III) isolated as described supra can be acidified to form the acid salt compound of formula (IIIa):
  • syn isomer compound of formula (III) can be utilized to produce the corresponding syn -5- ⁇ 3-[4-(10,11-difluoromethano-dibenzosuber-5-yl)piperazin-1-yl]-2-hydroxypropoxy)quinoline trihydrochloride compound of formula (XII) essentially as shown above for the free base of the anti isomer (IVa).
  • the reaction mixture was filtered through paper and the filter cake was washed with 200 mL of a 3:1 mixture of MTBE and methylene chloride.
  • the filtrate was washed with 200 mL of water and the aqueous layer was extracted four times with 100 mL of 3:1 MTBE/ methylene chloride.
  • the combined organic layers were dried over 30 grams of magnesium sulfate and the dried solution was then stirred with 50 grams of basic alumina for 30 minutes.
  • the alumina was removed by filtration and the filter cake was washed with 200 mL of 3:1 MTBE/methylene chloride.
  • the filtrate was concentrated to a volume of 100 mL, 300 mL of MTBE were added, and the solution was again concentrated to 80 mL.
  • the cooled reaction mixture was poured into water (1.8 L) and extracted with ether (1.8 L). The organic phase was washed with water, dried over sodium sulfate (Na 2 SO 4 ), and evaporated.
  • the reaction was cooled to ambient temperature and then combined with 400 mL of ethyl acetate and 75 g of diatomaceous earth. The solids were removed by filtration and washed with 300 mL of ethyl acetate. The washes and filtrate were combined and the ethyl acetate was removed by concentration under vacuum leaving 635 g of dark liquid. The dark liquid was cooled to 18 °C and to this was added, over 15 minutes, 6.62 g (0.175 mol) of sodium borohydride (as a 12% by wt solution in 14 M NaOH). After stirring for 2 h the reaction was quenched by careful addition of 900 mL of a 1:3.5:4.5 solution of conc.
  • the reaction was cooled to about 7 °C and stirred for 30 minutes at that temperature.
  • the reaction mixture was filtered to remove the precipitated syn -isomer (III) and the filter cake was washed with 250 mL of acetonitrile.
  • the combined filtrate and wash were concentrated under vacuum to 262.4 grams of a foam which was dissolved in 450 mL of acetonitrile with heating.
  • the solution was cooled to about 12 °C in an ice bath and stirred for 1 hour at that temperature.
  • the precipitated syn -piperazine compound of formula (III) was filtered and washed with 125 ml of acetonitrile.
  • the eluent was concentrated to a volume of approximately 60 mL and heated to 65 °C with stirring.
  • a solution of HCl in ethanol (16.1 g at 0.135 g/g of solution, 59.6 mmol) was added dropwise over 10 minutes and the resultant product solution was seeded, causing the trihydrochloride salt to precipitate.
  • the mixture was allowed to cool to ambient temperature and stirred slowly (less than 100RPM) for 2 hours.
  • syn isomer compound of formula (III) isolated as described supra can be utilized to produce the corresponding syn -5- ⁇ 3-[4-(10,11-difluoromethano-dibenzosuber-5-yl)piperazin-1-yl]-2-hydroxypropoxy ⁇ quinoline trihydrochloride (XII) essentially as shown below for the free base of the anti isomer (IVa) in step 6.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Quinoline Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)

Claims (13)

  1. Procédé de préparation d'un composé répondant à la formule (IVa) :
    Figure 00480001
    dans laquelle HX est un acide, comprenant les étapes consistant à :
    (a) dissoudre un composé répondant à la formule (II) :
    Figure 00480002
    dans de l'acétonitrile pour former une solution ;
    (b) cristalliser un composé stéréoisomère syn répondant à la formule (III) :
    Figure 00480003
    à partir de la solution de (II) ;
    (c) éliminer l'acétonitrile du filtrat pour donner un mélange enrichi en un composé stéréoisomère anti répondant à la formule (IV) :
    Figure 00490001
    (d) ajouter un acide choisi dans le groupe constitué du chlorure d'hydrogène, du bromure d'hydrogène et de l'acide camphorsulfonique, et un solvant choisi dans le groupe constitué du chlorure de méthylène, de l'éthanol et de l'acétate d'éthyle audit mélange enrichi ; et
    (e) cristalliser le composé stéréoisomère anti répondant à la formule (IVa).
  2. Procédé selon la revendication 1, dans lequel l'acide est le bromure d'hydrogène.
  3. Procédé selon la revendication 2, dans lequel le solvant est l'acétate d'éthyle ou le chlorure de méthylène.
  4. Procédé selon la revendication 1, dans lequel l'acide est l'acide chlorhydrique.
  5. Procédé selon la revendication 4, dans lequel le solvant est l'acétate d'éthyle.
  6. Procédé de préparation d'un composé répondant à la formule (V) :
    Figure 00500001
       ledit procédé comprenant la préparation de l'isomère anti (IVa) selon l'une quelconque des revendications 1 à 5 et la réaction du stéréoisomère anti (IVa) sous la forme d'une base libre, avec le (R)-1-(5-quinoléinyloxy)-2,3-époxypropane pour donner le composé répondant à la formule (V).
  7. Procédé de préparation d'un composé répondant à la formule (I) :
    Figure 00500002
       ledit procédé comprenant la préparation du composé répondant à la formule (V) selon la revendication 6 et la réaction du chlorure d'hydrogène avec le composé (V) pour former un composé répondant à la formule (I).
  8. Procédé de préparation d'un composé répondant à la formule (IIIa) :
    Figure 00500003
    dans laquelle HX est un acide, comprenant les étapes consistant à :
    (a) dissoudre un composé répondant à la formule (II) :
    Figure 00510001
    dans de l'acétonitrile pour former une solution ;
    (b) cristalliser le stéréoisomère syn (III) :
    Figure 00510002
    (c) ajouter un acide choisi dans le groupe constitué du chlorure d'hydrogène, du bromure d'hydrogène et de l'acide camphorsulfonique, et un solvant choisi dans le groupe constitué du chlorure de méthylène, de l'éthanol et de l'acétate d'éthyle au stéréoisomère syn (III) ; et
    (d) cristalliser le composé stéréoisomère syn répondant à la formule (IIIa).
  9. Procédé de préparation d'un composé répondant à la formule (XI) :
    Figure 00510003
       ledit procédé comprenant la préparation du stéréoisomère syn (III) selon la revendication 8 et la réaction du stéréoisomère syn (III) avec le (R)-1-(5-quinoléinyloxy)-2,3-époxypropane pour donner le composé isomère syn (XI).
  10. Procédé de préparation d'un composé répondant à la formule (XII) :
    Figure 00520001
       ledit procédé comprenant la préparation du composé isomère syn (XI) selon la revendication 9 et la réaction du chlorure d'hydrogène avec le composé (XI) pour former le composé répondant à la formule (XII).
  11. Composé répondant à la formule (IVa) :
    Figure 00520002
       dans laquelle HX est un acide choisi dans le groupe constitué du chlorure d'hydrogène, du bromure d'hydrogène, de l'acide camphorsulfonique et de l'acide sulfurique.
  12. Composé répondant à la formule (IIIa) :
    Figure 00520003
       dans laquelle HX est un acide choisi dans le groupe constitué du chlorure d'hydrogène, du bromure d'hydrogène, de l'acide camphorsulfonique et de l'acide sulfurique.
  13. Procédé de préparation d'un composé répondant à la formule (IVa) :
    Figure 00530001
    comprenant les étapes consistant à :
    (a) convertir la 10,11-dibenzosubérénone, illustrée ci-dessous :
    Figure 00530002
    en un alcool (ii) en une étape opérationnelle
    Figure 00530003
    (b) faire réagir l'alcool (ii) avec un agent d'halogénation pour former le composé (1a ,6 ,10b)-6-halogéno-1,1-difluoro-1,1a,6,10b-tétrahydrodibenzo[a,e]cyclopropa[c]cycloheptène (iii) :
    Figure 00540001
       dans lequel X représente l, Br ou Cl;
    (c) faire réagir le composé (1a ,6 ,10b )-6-halogéno-1,1-difluoro-1,1a,6,10b-tétrahydrodibenzo[a,e]cyclopropa[c]cycloheptène (iii) avec de la pipérazine dans un solvant pour former le mélange des composés pipérazines syn (III) :
    Figure 00540002
    et anti (IV) :
    Figure 00540003
    (d) séparer le composé de formule III du composé de formule IV.
EP00935852A 1999-06-03 2000-05-30 Procede de preparation d'un derive de 10,11-methanodibenzosuberane Expired - Lifetime EP1198462B1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US13728499P 1999-06-03 1999-06-03
US137284P 1999-06-03
PCT/US2000/011863 WO2000075132A1 (fr) 1999-06-03 2000-05-30 Procede de preparation d'un derive de 10,11-methanodibenzosuberane

Publications (2)

Publication Number Publication Date
EP1198462A1 EP1198462A1 (fr) 2002-04-24
EP1198462B1 true EP1198462B1 (fr) 2004-09-29

Family

ID=22476646

Family Applications (1)

Application Number Title Priority Date Filing Date
EP00935852A Expired - Lifetime EP1198462B1 (fr) 1999-06-03 2000-05-30 Procede de preparation d'un derive de 10,11-methanodibenzosuberane

Country Status (10)

Country Link
US (2) US6570016B1 (fr)
EP (1) EP1198462B1 (fr)
JP (1) JP2003501425A (fr)
AT (1) ATE277922T1 (fr)
AU (1) AU5125200A (fr)
CA (1) CA2375283A1 (fr)
DE (1) DE60014386T2 (fr)
ES (1) ES2228534T3 (fr)
PE (1) PE20010291A1 (fr)
WO (1) WO2000075132A1 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6207392B1 (en) * 1997-11-25 2001-03-27 The Regents Of The University Of California Semiconductor nanocrystal probes for biological applications and process for making and using such probes
ES2228534T3 (es) * 1999-06-03 2005-04-16 Eli Lilly And Company Procedimiento de preparacion de un derivado de 10,11-metanodibenzosuberano.
CA2442608A1 (fr) 2001-04-25 2002-11-07 Eli Lilly And Company Sel de chlorhydrate cristallin de (2r)-anti-5{3-¬-4-(10,11- difluoromethanodibenzosuber-5-yl)piperazine-1-yl|-2- hydroxypoxy}quinoline
JP2009505106A (ja) * 2005-08-19 2009-02-05 ナノスフェアー インコーポレイテッド Ｄｎａ及び抗体を含むハイブリッド基板を調製するための方法及びその使用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2125285T3 (es) * 1992-07-31 1999-03-01 Bristol Myers Squibb Co Derivados inhibidores de la reabsorcion de adenosina de difenil-oxazoles, tiazoles e imidazoles.
US5643909A (en) * 1993-04-19 1997-07-01 Syntex (U.S.A.) Inc. 10,11-Methanodibenzosuberane derivatives
JPH10504324A (ja) * 1995-06-07 1998-04-28 デイド、ケミストリー、システムズ、インコーポレイテッド 薬物の免疫原その他の接合体の製造
US6025359A (en) * 1996-06-17 2000-02-15 Eli Lilly And Company Drug resistance and multidrug resistance modulators
EP0844244A1 (fr) * 1996-11-22 1998-05-27 Eli Lilly And Company Modulateurs de résistance à un ou plusieurs médicaments
ES2228534T3 (es) * 1999-06-03 2005-04-16 Eli Lilly And Company Procedimiento de preparacion de un derivado de 10,11-metanodibenzosuberano.
TWI267511B (en) * 1999-06-03 2006-12-01 Lilly Co Eli Process for preparing 10,11-methanobenzosuberane derivatives

Also Published As

Publication number Publication date
ATE277922T1 (de) 2004-10-15
EP1198462A1 (fr) 2002-04-24
US6570016B1 (en) 2003-05-27
WO2000075132A1 (fr) 2000-12-14
DE60014386T2 (de) 2005-10-13
AU5125200A (en) 2000-12-28
PE20010291A1 (es) 2001-03-07
CA2375283A1 (fr) 2000-12-14
DE60014386D1 (de) 2004-11-04
JP2003501425A (ja) 2003-01-14
ES2228534T3 (es) 2005-04-16
US6624304B1 (en) 2003-09-23

Similar Documents

Publication Publication Date Title
US5643909A (en) 10,11-Methanodibenzosuberane derivatives
EP1886998A1 (fr) Procédés de purification du montelukast et ses sels d'amine
JP5819284B2 (ja) オロパタジンの製造方法
WO2016142819A2 (fr) Nouveau procédé de préparation de ranolazine
EP1198462B1 (fr) Procede de preparation d'un derive de 10,11-methanodibenzosuberane
EP0107804B1 (fr) Dérivés de l'acide 3-méthylflavone-8-carboxylique et leur procédé de préparation
IL182439A (en) Intermediates useful for the preparation of aripiprazole and methods for the preparation of the intermediates and aripiprazole
KR20020019902A (ko) 피페라진 고리 함유 화합물의 신규한 합성법 및 결정화법
US3978085A (en) Process for benz[f]-2,5-oxazocines
CN113336703B (zh) 1,3,4,5-四取代1h-吡唑衍生物的合成
WO2009011654A1 (fr) Procédé de préparation de spiropipéridines cycliques
JPS6368568A (ja) ｐ−アミノフエノ−ル誘導体
JP2001521498A (ja) Ｏ−（３−アミノ−２−ヒドロキシ−プロピル）−ヒドロキシミック酸ハロゲン化物の製造方法
US4017490A (en) Pyrido (3,4-d)pyridazines
EP1501802B1 (fr) Procede de preparation de derives de quinoline
EP0105484B1 (fr) Dérivés de l'acide 3-propionylsalicylique et leur procédé de préparation
CA2378735A1 (fr) Procede de preparation de derives de 10,11-methanobenzosuberane
EP1566381B1 (fr) Procede de production de 1- 2-(benzimidazol-2-yl-thio)ethyl piperazine ou de sels de celle-ci
JP2001199985A (ja) 高純度フェノチアジン化合物とその製造方法、およびその中間体の製造方法、並びにその中間体の原料の水和物と新規結晶
EP2297122B1 (fr) Nouveau procédé pour la préparation de la lévocétirizine et de ses intermédiaires
JPH09278773A (ja) オキセピノール誘導体の製造方法
JPS628114B2 (fr)
WO2006018703A2 (fr) Procedes de preparation de la narwedine et son utilisation dans la synthese de galantamine
JPS63208557A (ja) 四級アンモニウム塩

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20020103

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

AX Request for extension of the european patent

Free format text: AL;LT;LV;MK;RO;SI

17Q First examination report despatched

Effective date: 20020523

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE PATENT HAS BEEN GRANTED

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20040929

Ref country code: AT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20040929

Ref country code: NL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20040929

Ref country code: BE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20040929

Ref country code: CH

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20040929

Ref country code: FI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20040929

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

REF Corresponds to:

Ref document number: 60014386

Country of ref document: DE

Date of ref document: 20041104

Kind code of ref document: P

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20041229

Ref country code: DK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20041229

Ref country code: GR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20041229

LTIE Lt: invalidation of european patent or patent extension

Effective date: 20040929

NLV1 Nl: lapsed or annulled due to failure to fulfill the requirements of art. 29p and 29m of the patents act
REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

REG Reference to a national code

Ref country code: ES

Ref legal event code: FG2A

Ref document number: 2228534

Country of ref document: ES

Kind code of ref document: T3

ET Fr: translation filed
PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: CY

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20050530

Ref country code: IE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20050530

Ref country code: LU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20050530

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MC

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20050531

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

26N No opposition filed

Effective date: 20050630

REG Reference to a national code

Ref country code: IE

Ref legal event code: MM4A

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: PT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20050228

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: ES

Payment date: 20090605

Year of fee payment: 10

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: IT

Payment date: 20090516

Year of fee payment: 10

Ref country code: FR

Payment date: 20090515

Year of fee payment: 10

Ref country code: DE

Payment date: 20090529

Year of fee payment: 10

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: GB

Payment date: 20090527

Year of fee payment: 10

GBPC Gb: european patent ceased through non-payment of renewal fee

Effective date: 20100530

REG Reference to a national code

Ref country code: FR

Ref legal event code: ST

Effective date: 20110131

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20100530

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: DE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20101201

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: FR

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20100531

REG Reference to a national code

Ref country code: ES

Ref legal event code: FD2A

Effective date: 20110714

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: ES

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20110704

Ref country code: GB

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20100530

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: ES

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20100531